Bio-Rad Laboratories (NYSE:BIO) Sets New 1-Year High After Earnings Beat

Bio-Rad Laboratories, Inc. (NYSE:BIO)’s share price reached a new 52-week high during trading on Wednesday following a stronger than expected earnings report. The company traded as high as $352.63 and last traded at $346.99, with a volume of 26403 shares trading hands. The stock had previously closed at $332.88.

The medical research company reported $2.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.75 by $0.87. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The firm had revenue of $651.00 million during the quarter, compared to analysts’ expectations of $623.99 million. During the same period in the prior year, the company earned $2.61 EPS. The firm’s revenue was down .1% on a year-over-year basis.

Key Headlines Impacting Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Q2 earnings topped expectations. Bio-Rad reported adjusted earnings of $2.62 per share, well above the $1.75 consensus estimate cited by MarketBeat and the $2.34 estimate from Zacks. Earnings were also slightly higher than the $2.61 reported a year earlier. Bio-Rad Laboratories Beats Q2 Earnings Estimates
• Positive Sentiment: Revenue and cash flow exceeded forecasts. Quarterly revenue was $651 million, above the approximately $624 million analyst estimate, while operating cash flow reached $98.7 million. Cash and equivalents increased to $517 million, supporting the company’s balance-sheet flexibility. Bio-Rad Laboratories Earnings Report
• Neutral Sentiment: Growth remained essentially flat. Revenue declined 0.1% year over year, although gross profit improved modestly to $345.8 million. Operating profit eased to $72.6 million, indicating that the earnings beat did not come from strong top-line growth. Bio-Rad Laboratories Second-Quarter Results
• Negative Sentiment: Restructuring creates near-term uncertainty. Bio-Rad plans to cut jobs and close facilities, a move intended to reduce costs but also signaling pressure on operations and demand. Details on the scale and financial impact of the actions may remain a focus for investors. Bio-Rad Laboratories to Cut Jobs and Close Facilities
• Negative Sentiment: Full-year revenue guidance was cautious. Bio-Rad forecast fiscal 2026 revenue of $2.5 billion to $2.6 billion, slightly below the roughly $2.6 billion consensus estimate. With the stock trading near its 52-week high and at an elevated valuation, investors appear to be demanding stronger growth, limiting the positive reaction to the earnings beat.

Analyst Upgrades and Downgrades

BIO has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Monday. Wells Fargo & Company dropped their price objective on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. Royal Bank Of Canada initiated coverage on Bio-Rad Laboratories in a research report on Friday, May 15th. They issued an “outperform” rating and a $320.00 target price on the stock. Citigroup cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. Finally, Zacks Research downgraded shares of Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $303.33.

Hedge Funds Weigh In On Bio-Rad Laboratories

A number of hedge funds have recently bought and sold shares of BIO. Royal Bank of Canada increased its holdings in Bio-Rad Laboratories by 25.2% in the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock valued at $7,382,000 after buying an additional 6,100 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after buying an additional 32,874 shares during the last quarter. Empowered Funds LLC grew its position in shares of Bio-Rad Laboratories by 14.8% in the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after acquiring an additional 199 shares in the last quarter. Jane Street Group LLC grew its position in shares of Bio-Rad Laboratories by 95.3% in the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock worth $9,105,000 after acquiring an additional 18,239 shares in the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Bio-Rad Laboratories by 13.5% in the 2nd quarter. Cetera Investment Advisers now owns 2,192 shares of the medical research company’s stock valued at $529,000 after acquiring an additional 260 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Performance

The company has a 50-day moving average of $301.02 and a 200-day moving average of $287.81. The firm has a market capitalization of $9.19 billion, a price-to-earnings ratio of 56.60 and a beta of 1.06. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.